Details of the Drug

General Information of Drug (ID: DMRL3AB)

Drug Name

Famotidine

Synonyms

Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide

Indication

Disease Entry	ICD 11	Status	REF
Gastric ulcer	DA60	Approved	[1]
Gastrinoma	2C10.1	Approved	[1]
Peptic esophagitis	N.A.	Approved	[1]
Peptic ulcer	DA61	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antiulcer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

337.5

Logarithm of the Partition Coefficient (xlogp)

-0.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 6.6 mL/min/kg [5]
Elimination: 67% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.97661 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.84% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Bone marrow failure	Not Available	IL3	OT0CQ35N	[7]
Bone marrow failure	Not Available	CSF2	OT1M7D28	[7]
Bone marrow failure	Not Available	CSF3R	OTXRAY6X	[7]
-----------

Chemical Identifiers

Formula: C8H15N7O2S3
IUPAC Name: 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Canonical SMILES: C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
InChI: InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChIKey: XUFQPHANEAPEMJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5702160
ChEBI ID: CHEBI:4975
CAS Number: 76824-35-6
DrugBank ID: DB00927
TTD ID: D0K0OZ
VARIDT ID: DR00278
INTEDE ID: DR0680
ACDINA ID: D00518

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Antagonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[9]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[10]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Gene/Protein Processing	[12]
Fibroblast growth factor 21 (FGF21)	OT3RXVRD	FGF21_HUMAN	Gene/Protein Processing	[13]
Gastrin (GAST)	OTD0IP9N	GAST_HUMAN	Gene/Protein Processing	[14]
Granulocyte colony-stimulating factor receptor (CSF3R)	OTXRAY6X	CSF3R_HUMAN	Drug Response	[7]
Granulocyte-macrophage colony-stimulating factor (CSF2)	OT1M7D28	CSF2_HUMAN	Drug Response	[7]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Gene/Protein Processing	[15]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[15]
Interleukin-3 (IL3)	OT0CQ35N	IL3_HUMAN	Drug Response	[7]
Organic anion transporter 3 (SLC22A8)	OT8BY933	S22A8_HUMAN	Regulation of Drug Effects	[9]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[16]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Famotidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[17]
Cefuroxime	DMSIMD8	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Cefuroxime.	Acute bronchitis [CA42]	[18]
Glibenclamide	DM8JXPZ	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Glibenclamide.	Acute diabete complication [5A2Y]	[19]
Glipizide	DMZA5PQ	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Glipizide.	Acute diabete complication [5A2Y]	[19]
Ivosidenib	DM8S6T7	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[20]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Midostaurin.	Acute myeloid leukaemia [2A60]	[20]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Idarubicin.	Acute myeloid leukaemia [2A60]	[20]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Oliceridine.	Acute pain [MG31]	[20]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Famotidine and Rivastigmine.	Alzheimer disease [8A20]	[21]
Bepridil	DM0RKS4	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Bepridil.	Angina pectoris [BA40]	[20]
Dronedarone	DMA8FS5	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Dronedarone.	Angina pectoris [BA40]	[20]
Bedaquiline	DM3906J	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Cilostazol.	Arterial occlusive disease [BD40]	[20]
Posaconazole	DMUL5EW	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Posaconazole.	Aspergillosis [1F20]	[22]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Levalbuterol.	Asthma [CA23]	[20]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Pirbuterol.	Asthma [CA23]	[20]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Famotidine caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[23]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Salbutamol.	Asthma [CA23]	[20]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Formoterol.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[20]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[20]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Famotidine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[21]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Cefpodoxime	DMJUNY5	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[18]
Bacampicillin	DMP54C7	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[18]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Cefditoren	DMSUVM1	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[24]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Vismodegib	DM5IXKQ	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Vismodegib.	Basal cell carcinoma [2C32]	[20]
Pexidartinib	DMS2J0Z	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[25]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Eribulin.	Breast cancer [2C60-2C6Y]	[20]
Lapatinib	DM3BH1Y	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Lapatinib.	Breast cancer [2C60-2C6Y]	[26]
HKI-272	DM6QOVN	Major	Decreased absorption of Famotidine due to altered gastric pH caused by HKI-272.	Breast cancer [2C60-2C6Y]	[20]
Bosutinib	DMTI8YE	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Bosutinib.	Breast cancer [2C60-2C6Y]	[26]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[20]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Isoproterenol.	Conduction disorder [BC63]	[20]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Halothane.	Corneal disease [9A76-9A78]	[20]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Sevoflurane.	Corneal disease [9A76-9A78]	[20]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Probucol.	Coronary atherosclerosis [BA80]	[20]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Famotidine caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[23]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Pasireotide.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Osilodrostat.	Cushing syndrome [5A70]	[20]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Clomipramine.	Depression [6A70-6A7Z]	[20]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Doxepin.	Depression [6A70-6A7Z]	[20]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Maprotiline.	Depression [6A70-6A7Z]	[20]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[20]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Deutetrabenazine.	Dystonic disorder [8A02]	[20]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Ingrezza.	Dystonic disorder [8A02]	[20]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Solifenacin.	Functional bladder disorder [GC50]	[20]
Itraconazole	DMCR1MV	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Itraconazole.	Fungal infection [1F29-1F2F]	[27]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[28]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[20]
GS-5885	DMSL3DX	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by GS-5885.	Hepatitis virus infection [1E50-1E51]	[29]
Fosamprenavir	DM4W9B3	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Fosamprenavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Saquinavir	DMG814N	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Rilpivirine	DMJ0QOW	Major	Decreased absorption of Famotidine due to altered gastric pH caused by Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Atazanavir	DMSYRBX	Major	Decreased absorption of Famotidine due to altered gastric pH caused by Atazanavir.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Raltegravir	DMYURI6	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Probenecid	DMMFWOJ	Minor	Decreased elimination of Famotidine caused by Probenecid mediated competitive inhibition of renal tubular secretion.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[33]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Famotidine caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[34]
Crizotinib	DM4F29C	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Crizotinib.	Lung cancer [2C25]	[20]
Ceritinib	DMB920Z	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Ceritinib.	Lung cancer [2C25]	[35]
Dacomitinib	DMOH8VY	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Dacomitinib.	Lung cancer [2C25]	[26]
Osimertinib	DMRJLAT	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Osimertinib.	Lung cancer [2C25]	[20]
Selpercatinib	DMZR15V	Major	Decreased absorption of Famotidine due to altered gastric pH caused by Selpercatinib.	Lung cancer [2C25]	[26]
Lumefantrine	DM29GAD	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lumefantrine.	Malaria [1F40-1F45]	[20]
Halofantrine	DMOMK1V	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Halofantrine.	Malaria [1F40-1F45]	[20]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Hydroxychloroquine.	Malaria [1F40-1F45]	[20]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Primaquine.	Malaria [1F40-1F45]	[20]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[20]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[20]
Acalabrutinib	DM7GCVW	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Acalabrutinib.	Mature B-cell lymphoma [2A85]	[36]
Ponatinib	DMYGJQO	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Ponatinib.	Mature B-cell lymphoma [2A85]	[20]
Vemurafenib	DM62UG5	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Vemurafenib.	Melanoma [2C30]	[20]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and LGX818.	Melanoma [2C30]	[20]
Dabrafenib	DMX6OE3	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Dabrafenib.	Melanoma [2C30]	[20]
Panobinostat	DM58WKG	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Panobinostat.	Multiple myeloma [2A83]	[20]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Famotidine and Thalidomide.	Multiple myeloma [2A83]	[20]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Famotidine and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Moderate	Increased risk of atrioventricular block by the combination of Famotidine and Fingolimod.	Multiple sclerosis [8A40]	[37]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Famotidine and Ozanimod.	Multiple sclerosis [8A40]	[38]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Romidepsin.	Mycosis fungoides [2B01]	[20]
Nilotinib	DM7HXWT	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Nilotinib.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Major	Decreased absorption of Famotidine due to altered gastric pH caused by Dasatinib.	Myeloproliferative neoplasm [2A20]	[39]
Prasugrel	DM7MT6E	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[40]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Promethazine.	Nausea/vomiting [MD90]	[20]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Entrectinib.	Non-small cell lung cancer [2C25]	[20]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lofexidine.	Opioid use disorder [6C43]	[20]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Rucaparib.	Ovarian cancer [2C73]	[20]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Triclabendazole.	Parasitic worm infestation [1F90]	[20]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Pimavanserin.	Parkinsonism [8A00]	[20]
Lefamulin	DME6G97	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lefamulin.	Pneumonia [CA40]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Degarelix.	Prostate cancer [2C82]	[20]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and ABIRATERONE.	Prostate cancer [2C82]	[20]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Enzalutamide.	Prostate cancer [2C82]	[20]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Relugolix.	Prostate cancer [2C82]	[20]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Bicalutamide.	Prostate cancer [2C82]	[20]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[20]
Axitinib	DMGVH6N	Minor	Decreased absorption of Famotidine due to altered gastric pH caused by Axitinib.	Renal cell carcinoma [2C90]	[41]
Gatifloxacin	DMSL679	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[20]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Mesoridazine.	Schizophrenia [6A20]	[20]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Aripiprazole.	Schizophrenia [6A20]	[20]
Iloperidone	DM6AUFY	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Iloperidone.	Schizophrenia [6A20]	[20]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Paliperidone.	Schizophrenia [6A20]	[20]
Amisulpride	DMSJVAM	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Amisulpride.	Schizophrenia [6A20]	[20]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Asenapine.	Schizophrenia [6A20]	[20]
Pimozide	DMW83TP	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Pimozide.	Schizophrenia [6A20]	[20]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[20]
Vandetanib	DMRICNP	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[20]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Pitolisant.	Somnolence [MG42]	[20]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[20]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Lenvatinib.	Thyroid cancer [2D10]	[20]
Tolbutamide	DM02AWV	Moderate	Decreased absorption of Famotidine due to altered gastric pH caused by Tolbutamide.	Type 2 diabetes mellitus [5A11]	[19]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Procainamide	DMNMXR8	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[20]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[20]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[20]
Amiodarone	DMUTEX3	Moderate	Increased risk of prolong QT interval by the combination of Famotidine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[20]
-----------


⏷ Show the Full List of 128 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben	E00543	23663626	Antimicrobial preservative
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
Xanthan gum	E00694	Not Available	Bioadhesive material; Emulsifying agent; Gelling agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Famotidine 20 mg tablet	20 mg	Chewable Tablet	Oral
Famotidine 40mg/5ml for suspension	40mg/5ml	For Suspension	Oral
Famotidine 10mg/ml injectable	10mg/ml	Injectable	Injection
Famotidine 20mg tablet	20mg	Tablet	Oral
Famotidine 10 mg tablet	10 mg	Oral Tablet	Oral
Famotidine 20 mg tablet	20 mg	Oral Tablet	Oral
Famotidine 40 mg tablet	40 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Famotidine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074).
3	ClinicalTrials.gov (NCT04370262) Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
9	Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
10	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
11	Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
12	Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3/-catenin signaling pathway in the SH-SY5Y cell line. Chem Biol Interact. 2019 Dec 1;314:108823. doi: 10.1016/j.cbi.2019.108823. Epub 2019 Sep 26.
13	Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. J Clin Gastroenterol. 1995;21 Suppl 1:S24-9.
14	Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
15	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
16	Hyperprolactinaemia during famotidine therapy. Lancet. 1993 Oct 2;342(8875):868. doi: 10.1016/0140-6736(93)92729-d.
17	Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
18	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
19	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
20	Cerner Multum, Inc. "Australian Product Information.".
21	Canadian Pharmacists Association.
22	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
23	Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
24	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
25	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
28	Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
29	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
30	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
31	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
32	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
33	Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T "The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers." J Clin Pharmacol 30 (1990): 50-6. [PMID: 2303581]
34	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
35	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
40	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
41	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.